Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:DNAC NYSE:IKT NYSE:JATT NYSE:PRME On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDNACSocial Capital Suvretta Holdings Corp. III$9.28-7.2%$9.56$8.03▼$10.55$237.94MN/A178,857 shs8,160 shsIKTInhibikase Therapeutics$1.52-3.8%$1.85$1.12▼$4.20$113M0.92200,395 shs83,516 shsJATTJATT Acquisition$1.50+7.1%$1.26$7.80▼$12.38$25.88MN/A41,322 shs471,519 shsPRMEPrime Medicine$4.04+8.0%$2.82$1.11▼$5.18$503.02M2.332.39 million shs4.71 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDNACSocial Capital Suvretta Holdings Corp. III0.00%0.00%0.00%0.00%0.00%IKTInhibikase Therapeutics-3.80%-14.12%-17.84%-32.44%+7.80%JATTJATT Acquisition-4.76%-16.67%+33.33%-4.76%-62.47%PRMEPrime Medicine+8.02%-4.04%+31.60%+140.48%-27.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDNACSocial Capital Suvretta Holdings Corp. IIIN/AN/AN/AN/AN/AN/AN/AN/AIKTInhibikase Therapeutics2.0854 of 5 stars3.33.00.00.01.50.01.3JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/APRMEPrime Medicine3.7469 of 5 stars4.41.00.00.03.05.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDNACSocial Capital Suvretta Holdings Corp. III 0.00N/AN/AN/AIKTInhibikase Therapeutics 2.50Moderate Buy$6.50327.63% UpsideJATTJATT Acquisition 0.00N/AN/AN/APRMEPrime Medicine 2.75Moderate Buy$9.25128.96% UpsideCurrent Analyst Ratings BreakdownLatest DNAC, PRME, JATT, and IKT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/16/2025PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$8.005/27/2025PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$10.00 ➝ $1.505/20/2025PRMEPrime MedicineJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $6.005/20/2025PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral5/20/2025PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral5/19/2025PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $12.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDNACSocial Capital Suvretta Holdings Corp. IIIN/AN/AN/AN/A($0.33) per shareN/AIKTInhibikase TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AJATTJATT AcquisitionN/AN/A$0.06 per share27.08($0.53) per shareN/APRMEPrime Medicine$3.85M141.28N/AN/A$1.37 per share2.95Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDNACSocial Capital Suvretta Holdings Corp. III-$2.33MN/A0.00∞N/AN/AN/AN/AN/AIKTInhibikase Therapeutics-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/AJATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/APRMEPrime Medicine-$198.13M-$1.61N/AN/AN/AN/A-107.87%-74.97%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDNACSocial Capital Suvretta Holdings Corp. IIIN/AN/AN/AN/AN/AIKTInhibikase TherapeuticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/APRMEPrime Medicine$1.4535.79%N/AN/A N/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDNACSocial Capital Suvretta Holdings Corp. IIIN/A0.110.11IKTInhibikase TherapeuticsN/A0.850.85JATTJATT AcquisitionN/A0.150.15PRMEPrime MedicineN/A6.506.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDNACSocial Capital Suvretta Holdings Corp. III94.13%IKTInhibikase Therapeutics3.81%JATTJATT Acquisition47.97%PRMEPrime Medicine70.37%Insider OwnershipCompanyInsider OwnershipDNACSocial Capital Suvretta Holdings Corp. IIIN/AIKTInhibikase Therapeutics7.30%JATTJATT Acquisition20.00%PRMEPrime Medicine22.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableDNACSocial Capital Suvretta Holdings Corp. III425.64 millionN/ANot OptionableIKTInhibikase Therapeutics674.34 million66.18 millionNot OptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionablePRMEPrime Medicine234134.50 million100.38 millionOptionableDNAC, PRME, JATT, and IKT HeadlinesRecent News About These CompaniesPrime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares4 hours ago | insidertrades.comPrime Medicine Halts Sales Agreement ProspectusAugust 1 at 8:50 PM | theglobeandmail.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesAugust 1 at 8:50 PM | finance.yahoo.comPrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional SharesAugust 1 at 4:01 PM | globenewswire.comPrime Medicine (NYSE:PRME) Shares Gap Down - Here's WhyAugust 1 at 1:11 PM | marketbeat.comPrime Medicine stock falls after pricing public offeringAugust 1 at 4:11 AM | za.investing.comJonesTrading Maintains a Buy on Prime Medicine (PRME)August 1 at 4:11 AM | msn.comPrime Medicine (NYSE:PRME) Trading Up 6.9% - Here's WhyJuly 31 at 2:54 PM | marketbeat.comPrime Medicine Announces Pricing of Public OfferingJuly 30 at 9:33 PM | globenewswire.comPrime Drink Group Extends Expiry Date of Its Rights Offering and Announces Delay in Filing Annual Financial StatementsJuly 30 at 9:11 PM | globenewswire.comPrime Medicine (NYSE:PRME) Trading Down 8.9% - Here's WhyJuly 30 at 4:32 PM | marketbeat.comPrime Medicine Announces Proposed Public Offering of Common StockJuly 30 at 4:01 PM | globenewswire.comPrime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?July 30 at 10:55 AM | zacks.com3 Genomics Stocks Worth Adding to Your Portfolio in 2025July 30 at 10:45 AM | zacks.comARK Investment Management LLC Sells 2,055,061 Shares of Prime Medicine, Inc. (NYSE:PRME)July 27, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Shares Sold by Nikko Asset Management Americas Inc.July 27, 2025 | marketbeat.comPrime Medicine, Inc. (NYSE:PRME) Receives $9.25 Consensus Price Target from BrokeragesJuly 27, 2025 | americanbankingnews.comPrime Medicine, Inc. (NYSE:PRME) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJuly 24, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Shares Up 23.3% - Here's WhyJuly 21, 2025 | marketbeat.comPrime Medicine (NYSE:PRME) Stock Price Down 6.6% - Time to Sell?July 18, 2025 | marketbeat.comWedbush Has Positive Forecast for Prime Medicine Q2 EarningsJuly 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDNAC, PRME, JATT, and IKT Company DescriptionsSocial Capital Suvretta Holdings Corp. III NASDAQ:DNACSocial Capital Suvretta Holdings Corp. III does not have significant operations. It focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on searching for a target business operating in the biotechnology industry and within the organ space sub-sector. Social Capital Suvretta Holdings Corp. III was incorporated in 2021 and is based in Henderson, Nevada.Inhibikase Therapeutics NYSE:IKT$1.52 -0.06 (-3.80%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.52 0.00 (0.00%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.JATT Acquisition NYSE:JATT$1.50 +0.10 (+7.14%) As of 08/1/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Prime Medicine NYSE:PRME$4.04 +0.30 (+8.02%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$4.34 +0.30 (+7.33%) As of 08/1/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
